Please assess the completion status of the following clinical trial:

Trial Title: Melatonin for Prevention of Metabolic Side Effects of Olanzapine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 year~* First episode schizophrenia (DSM-IV-TR)~* Ability to take medicine orally~* Eligible for starting olanzapine~Exclusion Criteria:~* Married women who are at reproductive age~* History of taking olanzapine in the recent 3 months~* History of allergy or intolerance to olanzapine~* History of significant head trauma ( causing loss of consciousness more than 5 minutes or neurological or cognitive sequels)~* Liver, kidney, cerebrovascular or cardiovascular disease~* Diabetes, metabolic syndrome~* Cancer~* Using antiepileptic (other than benzodiazepines for sleep) , antihypertensive, anticoagulant, anti-platelet drugs~* Using inhibitors or stimulants of hepatic isoenzymes that metabolize melatonin or olanzapine (e.g. omeprazole. rifampin, fluvoxamine, ciprofloxacin, carbamazepine, modafinil)~* Delirium~* Need for administration of other antipsychotics~* Substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: EXPERIMENTAL): Tablet melatonin 3 mg/day at 9 pm as intervention group for eight week
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (with the same shape and taste as melatonin) at 9 pm as control group

Based on this trial design, predict the completion outcome and termination type (if applicable).